Currently, small-molecule inhibitors targeting mutant IDH1, such as ivosidenib, are being investigated in preclinical and clinical studies as promising therapeutic options for IDH1-mutated CCA (112, 113). Here, IDH1 is linked to cholangiocarcinoma.